Robert J. More - Sep 17, 2021 Form 4 Insider Report for Tyra Biosciences, Inc. (TYRA)

Role
Director
Signature
/s/ John Healy, Attorney-in Fact
Stock symbol
TYRA
Transactions as of
Sep 17, 2021
Transactions value $
$2,500,000
Form type
4
Date filed
9/17/2021, 04:48 PM
Previous filing
Sep 14, 2021
Next filing
May 25, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TYRA Common Stock Conversion of derivative security +3.81M +3374.79% 3.92M Sep 17, 2021 See footnote F1, F2
transaction TYRA Common Stock Purchase $2.5M +156K +3.98% $16.00 4.08M Sep 17, 2021 See footnote F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TYRA Series A Preferred Stock Conversion of derivative security $0 -1.21M -100% $0.00* 0 Sep 17, 2021 Common Stock 3.15M See footnote F1, F2
transaction TYRA Series B Preferred Stock Conversion of derivative security $0 -255K -100% $0.00* 0 Sep 17, 2021 Common Stock 663K See footnote F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
F2 These securities are held directly by Alta Partners NextGen Fund II, L.P. (the "APNG II"). The Reporting Person is a managing director of the general partner of APNG II and shares voting and investment control with respect to the shares held by APNG II. The Reporting Person disclaims beneficial ownership of all shares held by APNG II, except to the extent of his pecuniary interest therein.